Abstract
Despite recent successes, metastatic colorectal cancer remains a difficult cancer to treat. Since the initial discovery that PI-3-Kinase/AKT signaling played an important part in the growth and survival of colorectal tumors, preclinical studies have suggested that inhibitors of this pathway may have a role to play as potential therapeutics. With the surge of inhibitors of PI-3-Kinase from both academia and pharmaceutical companies rapidly moving through early clinical trials, the question of whether these preclinical studies will translate to patients will soon be answered. However, the failure or success of these agents will depend on correctly identifying patients that may benefit, as has been seen with EGFR inhibitors recently approved for treating this disease. Determining the potential of PI-3-Kinase inhibitors in colorectal cancer will depend on factors such as correctly monitoring biomarkers and patient response, enriching clinical trials by proactively stratifying patients into populations based on markers shown to not only predict response to these inhibitors, but also markers which may predict for lack of response, and determining how to combine these inhibitors with both current cytotoxic therapies and approved and emerging targeted therapies with optimal benefit. How these goals may be achieved in the current oncology landscape is addressed in this review with an emphasis on how these agents fit the goal of achieving personalized medicine.
Keywords: PI3K, colorectal cancer, KRAS, PTEN, PIK3CA, AKT, PI-3-Kinase/, academia, leucovorin, irinotecan, cape-citabine, oxaliplatin, tumorgenesis, angiogenesis, Threonine, oncogenesis, cytotoxics, cetuxmab, Insulin-like growth factor 1, colorectal cells, heterozygosity, tumorigenesis, immunohistochemistry, mutant KRAS, malignancies, hyperglycemia, hyperinsulinemia, cetuximab, mesenchymal phenotype
Current Cancer Drug Targets
Title: PI-3-Kinase Inhibitors in Colorectal Cancer
Volume: 11 Issue: 2
Author(s): N. T. Ihle, G. Powis and S. Kopetz
Affiliation:
Keywords: PI3K, colorectal cancer, KRAS, PTEN, PIK3CA, AKT, PI-3-Kinase/, academia, leucovorin, irinotecan, cape-citabine, oxaliplatin, tumorgenesis, angiogenesis, Threonine, oncogenesis, cytotoxics, cetuxmab, Insulin-like growth factor 1, colorectal cells, heterozygosity, tumorigenesis, immunohistochemistry, mutant KRAS, malignancies, hyperglycemia, hyperinsulinemia, cetuximab, mesenchymal phenotype
Abstract: Despite recent successes, metastatic colorectal cancer remains a difficult cancer to treat. Since the initial discovery that PI-3-Kinase/AKT signaling played an important part in the growth and survival of colorectal tumors, preclinical studies have suggested that inhibitors of this pathway may have a role to play as potential therapeutics. With the surge of inhibitors of PI-3-Kinase from both academia and pharmaceutical companies rapidly moving through early clinical trials, the question of whether these preclinical studies will translate to patients will soon be answered. However, the failure or success of these agents will depend on correctly identifying patients that may benefit, as has been seen with EGFR inhibitors recently approved for treating this disease. Determining the potential of PI-3-Kinase inhibitors in colorectal cancer will depend on factors such as correctly monitoring biomarkers and patient response, enriching clinical trials by proactively stratifying patients into populations based on markers shown to not only predict response to these inhibitors, but also markers which may predict for lack of response, and determining how to combine these inhibitors with both current cytotoxic therapies and approved and emerging targeted therapies with optimal benefit. How these goals may be achieved in the current oncology landscape is addressed in this review with an emphasis on how these agents fit the goal of achieving personalized medicine.
Export Options
About this article
Cite this article as:
T. Ihle N., Powis G. and Kopetz S., PI-3-Kinase Inhibitors in Colorectal Cancer, Current Cancer Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/156800911794328448
DOI https://dx.doi.org/10.2174/156800911794328448 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity
Letters in Drug Design & Discovery Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy
Current Drug Therapy Role of AGEs in Diabetic Nephropathy
Current Pharmaceutical Design Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy
Current Medicinal Chemistry Circular RNAs in Eukaryotic Cells
Current Genomics Investigating the Association Between miR-608 rs4919510 and miR-149 rs2292832 with Colorectal Cancer in Iranian Population
MicroRNA Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry The Glutathione System as an Attractive Therapeutic Target
Drug Design Reviews - Online (Discontinued) Effects of Quercetin against Mycotoxin Induced Cytotoxicity: A Mini- Review
Current Nutrition & Food Science Sucrose Hydrolytic Enzymes: Old Enzymes for New Uses as Biocatalysts for Medical Applications
Current Topics in Medicinal Chemistry Phytosomal Curcumin Elicits Anti-tumor Properties Through Suppression of Angiogenesis, Cell Proliferation and Induction of Oxidative Stress in Colorectal Cancer
Current Pharmaceutical Design Plant Based Natural Products as Quorum Sensing Inhibitors in <i>E. Coli</i>: A Critical Review
Mini-Reviews in Medicinal Chemistry Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Current Signal Transduction Therapy Peptide Aptamers: Specific Inhibitors of Protein Function
Current Molecular Medicine Sentinel Node Imaging
Current Medical Imaging Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Phosphonate Analogues of 1α, 25 Dihydroxyvitamin D<sub>3</sub> are Promising Candidates for Antitumoural Therapies
Current Topics in Medicinal Chemistry